Related references
Note: Only part of the references are listed.Rab family of small GTPases: an updated view on their regulation and functions
Yuta Homma et al.
FEBS JOURNAL (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis
Shuyan Liu et al.
CELL DEATH AND DIFFERENTIATION (2021)
Internalized Activation of Membrane Receptors: From Phenomenon to Theory
Wenjin Wang et al.
TRENDS IN CELL BIOLOGY (2021)
The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer
Jinrui Zhang et al.
CELL DEATH AND DIFFERENTIATION (2020)
USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress
Yueguang Wu et al.
CELL DEATH & DISEASE (2020)
Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
Jinrui Zhang et al.
CELL COMMUNICATION AND SIGNALING (2019)
Functional analysis of deubiquitylating enzymes in tumorigenesis and development
Ji Cheng et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
Taishu Wang et al.
CELL COMMUNICATION AND SIGNALING (2018)
Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer
Taishu Wang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Ferdinandos Skoulidis et al.
CLINICAL CANCER RESEARCH (2017)
Meddling with Fate: The Proteasomal Deubiquitinating Enzymes
Stefanie A. H. de Poot et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Reticulon 3-dependent ER-PM contact sites control EGFR nonclathrin endocytosis
Giusi Caldieri et al.
SCIENCE (2017)
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
Katerina Politi et al.
CANCER CELL (2015)
Deubiquitinase inhibition as a cancer therapeutic strategy
Padraig D'Arcy et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells
Fabrizio Capuani et al.
NATURE COMMUNICATIONS (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Threshold-controlled ubiquitination of the EGFR directs receptor fate
Sara Sigismund et al.
EMBO JOURNAL (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Governance of Endocytic Trafficking and Signaling by Reversible Ubiquitylation
Michael J. Clague et al.
DEVELOPMENTAL CELL (2012)
ENDOCYTOSIS AND SIGNALING: CELL LOGISTICS SHAPE THE EUKARYOTIC CELL PLAN
Sara Sigismund et al.
PHYSIOLOGICAL REVIEWS (2012)
A small-molecule inhibitor of deubiquitinating enzyme USP14 inhibits Dengue virus replication
Dilip K. Nag et al.
VIRUS RESEARCH (2012)
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
Mikael Altun et al.
CHEMISTRY & BIOLOGY (2011)
Trimming of Ubiquitin Chains by Proteasome-associated Deubiquitinating Enzymes
Min Jae Lee et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Padraig D'Arcy et al.
NATURE MEDICINE (2011)
The therapeutic potential of deubiquitinating enzyme inhibitors
Frederic Colland
BIOCHEMICAL SOCIETY TRANSACTIONS (2010)
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
Gur Pines et al.
FEBS LETTERS (2010)
Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@
Byung Min Chung et al.
BMC CELL BIOLOGY (2009)
Endocytosis and intracellular trafficking of ErbBs
Alexander Sorkin et al.
EXPERIMENTAL CELL RESEARCH (2009)
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
Ayana Sawai et al.
CANCER RESEARCH (2008)
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation
Sara Sigismund et al.
DEVELOPMENTAL CELL (2008)
Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking
Chengyu Liang et al.
NATURE CELL BIOLOGY (2008)
Derailed endocytosis: an emerging feature of cancer
Yaron Mosesson et al.
NATURE REVIEWS CANCER (2008)
The MIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient epidermal growth factor receptor degradation
Paula E. Row et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Endocytosis:: the DUB version
Michael J. Clague et al.
TRENDS IN CELL BIOLOGY (2006)
The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation
PE Row et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Rab conversion as a mechanism of progression from early to late endosomes
J Rink et al.
CELL (2005)
AMSH is an endosome-associated ubiquitin isopeptidase
J McCullough et al.
JOURNAL OF CELL BIOLOGY (2004)